Makita Kenji, Hamamoto Yasushi, Kanzaki Hiromitsu, Nagasaki Kei, Kochi Yoshihiro, Kido Teruhito
Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan.
Department of Radiology, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan.
Oncol Lett. 2024 Aug 7;28(4):482. doi: 10.3892/ol.2024.14615. eCollection 2024 Oct.
The present study investigated the prognosis of patients who received palliative radiotherapy (RT) for bone metastases (BMs) from renal cell cancer (RCC), and assessed the prognostic factors specific to BMs from RCC. A total of 109 patients with RCC and BMs who underwent RT for the first time were included in the study. Prognostic factors were evaluated using multivariate analysis and a scoring system based on regression coefficients was devised. The median follow-up time was 9 months, and the 0.5-year overall survival (OS) rate was 73.0%. In the multivariate analysis, the significant prognostic factors were higher performance status (≥2), no control of the primary site, disseminated metastasis, lymph node metastasis and multiple BMs. A score of 1 point was assigned to each risk factor. The median OS times were 19.0 and 5.0 months in patients with a total score of ≤1 (n=49) and >1 (n=60), respectively (P<0.01). In conclusion, a comprehensive prognostic assessment using these factors may be useful for predicting the prognoses of patients with BMs from RCC. In addition, this scoring system may be useful in selecting the optimal RT dose.
本研究调查了接受姑息性放疗（RT）的肾细胞癌（RCC）骨转移（BMs）患者的预后，并评估了RCC骨转移特有的预后因素。共有109例首次接受RT治疗的RCC和BMs患者纳入本研究。采用多因素分析评估预后因素，并设计了基于回归系数的评分系统。中位随访时间为9个月，0.5年总生存率（OS）为73.0%。多因素分析显示，显著的预后因素包括较高的体能状态（≥2）、原发部位未控制、弥漫性转移、淋巴结转移和多发骨转移。每个危险因素计1分。总分≤1分（n = 49）和>1分（n = 60）的患者中位OS时间分别为19.0个月和5.0个月（P<0.01）。总之，使用这些因素进行综合预后评估可能有助于预测RCC骨转移患者的预后。此外，该评分系统可能有助于选择最佳放疗剂量。
